Teratogen update: azathioprine and 6-mercaptopurine.

نویسندگان

  • Janine E Polifka
  • J M Friedman
چکیده

Azathioprine (AZA) and its active metabolite, 6-mercaptopurine (6-MP), are purine analogues that interfere with the synthesis of adenine and guanine ribonucleosides. These ribonucleosides are important precursors of DNA and RNA. Because AZA and 6-MP act predominantly on rapidly dividing cells such as the T lymphocytes, these drugs are not only cytotoxic but also immunosuppressive and anti-inflammatory. The effects are dose-related, small doses of either drug are anti-inflammatory, but larger doses are immunosuppressive and cytotoxic (Goldstein, ’87). 6-MP has been used in cancer chemotherapy, primarily in childhood and adult leukemias and usually in combination with other drugs. 6-MP is also used to treat autoimmune diseases, such as inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) (Bermas and Hill, ’95; Ramsey-Goldman and Schilling, ’97). Initial oral doses for treatment of leukemia range between 2.5–5 mg/kg/d. For maintenance therapy of leukemia, doses range between 1.5–2.5 mg/kg/d. Similar doses (1.5–2.5 mg/kg/d) are used to treat IBD (Present et al., ’80; Botoman et al., ’98; USP DI, ’01), but the use of 6-MP as an immunosuppressant has been largely superseded by AZA, which has been shown to possess a better therapeutic index (Van Scoik et al., ’85; Goldstein, ’87; Chabner et al., ’96). AZA is no longer used as an antineoplastic agent (O̊stensen, ’92), but is employed in the treatment of autoimmune disorders at doses between 1–2.5 mg/kg/d and at doses between 1–5 mg/kg/d as part of immunosuppressive regimens to prevent transplant rejection (Botoman et al., ’98; USP DI, ’01). The majority of patients affected by autoimmune diseases are women, in whom the peak incidence occurs between 16 and 55 years of age (Weterman, ’89; Brent et al., ’97; Esplin and Branch, ’97). Successful treatment with cytotoxic and immunosuppressant drugs such as AZA has greatly improved the feasibility of pregnancy in affected women, many of whom must continue to take the medications throughout gestation to prevent relapse. Similarly, women who become pregnant after organ transplantation continue immunosuppressive therapy to prevent rejection if they have been on immunosuppressive therapy before pregnancy. In some patients who become ill with an immunopathic or malignant disease while pregnant, treatment with 6-MP or AZA may be initiated during gestation. The use of cytotoxic immunosuppressants during pregnancy raises concern about possible adverse effects in the developing embryo or fetus, but the potential teratogenicity of AZA and 6-MP is difficult to evaluate in humans. These agents are used to treat patients who have severe illness, and it is often impossible to determine if adverse effects that occur in the embryo/fetus resulted from a particular treatment, the maternal illness, or some other factor (Brent et al., ’97). Also, because of the severity of the illness and the complications that ensue, combination therapy is common. Use of drug combinations as well as variations in dose further hamper efforts to attribute an observed adverse effect to a particular treatment. This article will review human and animal data regarding the pharmacology of 6-MP and AZA and their adverse effects on the embryo and fetus.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.

BACKGROUND 6-Mercaptopurine and its prodrug azathioprine are effective medications for refractory inflammatory bowel disease. However, use of these drugs has been limited by concerns about their toxicity. Colonic delivery of azathioprine may reduce its systemic bioavailability and limit toxicity. AIM To determine the bioavailability of 6-mercaptopurine after administration of azathioprine via...

متن کامل

Divergent activities of human glutathione transferases in the bioactivation of azathioprine.

Azathioprine is a thiopurine prodrug clinically used for immunosuppression in the treatment of inflammatory diseases and in pharmacological regimens of organ transplantations. Its pharmacological action is based on the release of 6-mercaptopurine, but the biochemical processes underlying this biotransformation have remained obscure. In this investigation, human glutathione transferases (GSTs) f...

متن کامل

Simultaneous determination of azathioprine and its metabolite 6-mercaptopurine in human plasma using solid phase extraction-evaporation and liquid chromatography–positive electrospray tandem mass spectrometry

A simple, rapid, specific, sensitive and liquid chromatography coupled with tandem mass spectrophotometric method was developed and validated for the estimation of azathioprine and its metabolite 6-mercaptopurine in human plasma by using lamivudine and 6-mercaptopurine D3 as the internal standard. Azathioprine and 6mercaptopurine were extracted from human plasma by solid-phase extraction (SPE)-...

متن کامل

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

AIM We evaluated the effect of coadministration of sulphasalazine, mesalamine, and balsalazide on the pharmacokinetics and pharmacodynamics of azathioprine and 6-mercaptopurine. METHODS Thirty four patients with Crohn's disease receiving azathioprine or 6-mercaptopurine were enrolled in an eight week non-randomised parallel group drug interaction study and treated with mesalamine 4 g/day, sul...

متن کامل

Azathioprine in inflammatory bowel disease, a safe alternative?

Azathioprine and its metabolite 6-mercaptopurine are effective in the treatment of inflammatory bowel disease. They are mostly used for reduction of the use of steroids, maintenance therapy after remission induction by cyclosporin and treatment of fistulae in Crohn's disease. Adverse effects occur in about 15% of patients. The main side effects are pancreatitis, allergic reactions, fever and bo...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Teratology

دوره 65 5  شماره 

صفحات  -

تاریخ انتشار 2002